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accepted May 13,ecropsy studies have outlined the morphological characteristics of high-risk, or “vulnerable,” coronary plaque
segments, demonstrating the presence of inﬂammatory inﬁltrate and various compositional elements in patients
who succumbed to fatal intracoronary thrombosis. However, accumulating evidence in vivo relates the overall
burden of atherosclerosis, its rate of progression, and its subsequent ischemic potential with the risk for incident
clinical events. These observations, coupled with the efﬁcacy of contemporary medical therapies in reducing clinical
event rates, have important implications for trial design of future human in vivo evaluations of vulnerable coronary
plaque. (J Am Coll Cardiol 2014;63:1134–40) ª 2014 by the American College of Cardiology FoundationIn 1989, Muller et al. (1) described non–ﬂow-limiting
coronary stenoses that had a propensity to rupture and cause
acute myocardial infarctions (AMI) as “vulnerable” plaques.
This deﬁnition was formally revised by an international
panel of experts in 2004, to include plaques prone to rupture,
erosion, or containing a calciﬁed nodule, particularly in a
patient deemed systemically “vulnerable” (2). Nearly 25 years
later, the ability to consistently identify plaque segments
that predict incident coronary events remains a challenging
task, particularly in the current era of optimal medical
therapies that have altered the natural history of coronary
atheroma in vivo. More contemporary angiographic evalu-
ations of culprit lesions that resulted in AMI have demon-
strated the likelihood of rapid lesion progression in the
ensuing months before the occurrence of AMI (3). Accu-
mulating evidence also links ischemic coronary lesions with
incident coronary events. Whether AMIs are more likely to
immediately arise from within a mildly diseased coronary
segment (<50% angiographic stenosis severity) versus
a functionally signiﬁcant, or obstructive (>50% angiogra-
phic stenosis severity) lesion at the time of AMI, remains
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2013.Pathological Observations of Lesions
Causing Myocardial Infarction and
Mechanisms of Plaque Progression
Necropsy studies have taught us that plaque rupture and erosion
account for a majority of cases of intracoronary thrombosis and
microembolization, respectively, and these studies demonstrated
the presence ofmultiple healed plaque ruptures, with evidence of
layering (5,6). Stenosis severity within the majority of lesions
containing rupture was recently reported to be >75% cross-
sectional area narrowing (7), whereas the mean stenosis
severity in culprit lesions with erosions and downstream emboli
was74% (6). In a seminal pathological study using ex vivo arterial
perfusion techniques (to achieve optimal lumen dimensions) for
better estimating the extent of lumen compromise before tissue
ﬁxation, more than 70% of high-grade stenoses displayed prior
plaque disruption that presumably triggered enhanced smooth
muscle cell proliferation and plaque growth (8). It was thus felt
that silent plaque ruptures and healing (with lesion growth)
could either be a consequence of high-grade stenoses per se or
occur suddenly/episodically in lower-grade lesions, resulting in
rapid plaque growth before a myocardial infarction (MI). Either
way, silent plaque ruptures form an important component of
plaque wound healing in vivo, facilitating plaque progression.
This explains the discord between the frequency of observed
plaque rupture, symptoms, and clinical events (9,10). Addi-
tionally, the process of plaque rupture, healing, and progression
towards a high-grade stenosis appears to be phasic rather than
linear.The subclinical nature of this process suggests that current
attempts to prospectively identify speciﬁc morphological
features of plaque segments that predispose to future rupture,
erosion, and clinical events is likely to be an inefﬁcient process,
representing a difﬁcult challenge.
Abbreviations
and Acronyms
AMI = acute myocardial
infarction
IPH = intraplaque
hemorrhage
IVUS = intravascular
ultrasound
FFR = fractional ﬂow reserve
PCI = percutaneous coronary
intervention
LDL-C = low-density
lipoprotein cholesterol
ECG = electrocardiography
MACE = major adverse
cardiovascular event(s)
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1135Lesion progression observed with serial coronary angiography
appears unpredictable and nonlinear in course (11–14). Mech-
anisms underlying human coronary atheroma progression
presently remain limited to observations made at autopsy.
Nevertheless, these studies identiﬁed strong links between
intraplaque hemorrhage and atheroma progression (15). Lesion
progression is thought to occur via expansion of the necrotic
core, which in turn culminates in the formation of a more
advanced, vulnerable atheroma phenotype, or ﬁbroatheroma.
Leaky vasa vasorum, that permeate atherosclerotic plaque,
enable erythrocytes and inﬂammatory cells to extravasate.
Erythrocyte membranes thus form amajor source of intraplaque
lipid deposition and subsequent necrotic core expansion (16).
Therefore, imaging technologies that enable detection of
intraplaque hemorrhage in vivo may allow us to more reliably
predict coronary atheroma at risk for rapid lesion progression,
before possible MI.
Coronary Imaging of Lesions Before Causing MI
A series of retrospective angiographic studies from a patient
afﬂicted with AMI identiﬁed baseline culprit lesion severity
to range from 30% to 45% (17–21). However, common to
these studies was the prolonged time period (range 18 to 40
months) between baseline coronary angiography and the
sentinel AMI event (Table 1), coupled with limited numbers
of patients in each study.
Speciﬁc to the setting of AMI, a study by Ojio et al.
(22) investigated the unique situation of 20 patients
who happened to undergo elective coronary angiography
essentially within 1 week (mean time of 3  3 days)
before AMI. Ten of these patients underwent coronary an-
giography for investigation of exertional angina, and were
scheduled for elective percutaneous coronary intervention
(PCI) of the symptom-causing, obstructive lesion. Five
patients were asymptomatic at the time, undergoing surveil-
lance coronary angiography within 3 months of a prior coro-
nary angioplasty for another symptom-producing lesion.Table 1
Summary of Studies Speciﬁcally Evaluati
Baseline Angiographic Lesion Severity an
First Author (Ref. #) Study Period Patient Typ
Zaman et al. (3) 2003–2010 STEMI: 41
Ojio et al. (22) 1991–1997 STEMI group
STEMI group
Ambrose et al. (17) 1987 QWMI: 15
NQWMI: 8
Dacanay et al. (20) 1980–1991 QWMI: 32
NQWMI: 3
Little et al. (18) 1975–1985 29
Giroud et al. (19) 1972–1990 92
Hackett et al. (21) 1978–1985 10
Values are mean  SD or median (interquartile range). *SD not mentioned in
as a categorical variable. Adapted and modiﬁed with permission from Zama
NQWMI ¼ non–Q-wave myocardial infarction; QWMI ¼ Q-wave myocardialDespite an obstructive lesion
being found in the nonintervened
vessel, given the asymptomatic
status of the patient on antiplatelet
or anticoagulant therapy, further
PCI was not undertaken. Three
patients were felt to present with
coronary spasm and were treated
medically; the remaining 2 patients
were asymptomatic but demon-
strated electrocardiographic abnor-
malities, thus warranting coronary
angiography. These patients were
compared with 20 control patients
who underwent coronary angiog-
raphy 6 to 18 months (mean time
of 282  49 days) before AMI.
The mean diameter stenosis severity in the group undergoing
angiography 3 days pre-AMI was 71  12%. The mean
diameter stenosis severity close to 1-year pre-AMI was
30 18%, highlighting the presence of a more advanced lesion
as a substrate for AMI in these patients. Studies by Frobert
et al. (23),Brownet al. (24), andManoharan et al. (25)provided
further insight into the nature of culprit lesion severity in the
AMI setting treated with primary PCI. Acknowledging the
confounding presence of intracoronary thrombus leading to a
likely overestimation of stenosis severity, most culprit lesions
appeared angiographically severe by quantitative analysis.
Similarly, acknowledging the possibility of residual thrombus
burden, the angiographic severity of culprit lesions immedi-
ately after thrombolytic therapy for AMI (with either strep-
tokinase or recombinant tissue-type plasminogen activator),
and following an additional 3 weeks of systemic anti-
coagulation therapy, was >50% in a majority of patients (26).
Furthermore, post hoc analyses from the CASS (Coronary
Artery Surgery Study) found that lesions with>50% diameter
stenosis severity were independently associated with the
occurrence of AMI within 3 years (27). At 5 years, the initialng the Relationship Between
d Progression to MI
e: n
Baseline % Diameter
Stenosis
Interval Group
(Days)
40  24 720  600
1: 20 71  12 3  3
2: 20 30  18 282  49
34* 540 (30–2,520)
80* 990 (90–3,240)
44  25 1,200  840
8 23  35 1,320  900
44  15 690  690
N/Ay 660 (30–2,820)
30  15 690 (60–1,770)
study. yMean percent diameter stenosis not reported, represented only
n et al. (3).
infarction; STEMI ¼ ST-segment elevation myocardial infarction.
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1136stenosis severity predicted lesion progression (28). To add to
this, Zaman et al. (3) recently conducted a time-based analysis
to assess the angiographic severity of coronary stenoses leading
to anAMI. Similar to earlier conducted studies, 71%of patients
analyzed displayed a <50% diameter stenosis when the
angiogram was performed several months before the AMI.
However, 57% of lesions that were evaluated within 3 months
of an AMI had a stenosis severity of >50% (mean diameter
stenosis 59  31%).
A substudy from the COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation)
trial found that patients with AMI were more likely to have
had an originally deferred baseline coronary lesion that was
>50% in stenosis severity, with the average stenosis severity at
time of angiography for subsequent AMI being >70% (29).
The only independent predictor of AMI was an initial non-
revascularized lesion of>50% in stenosis severity. Themedian
follow-up time of lesions initially found to be >50% stenosis
severity was 0.59 years. In the medically treated group, 4% of
lesions that were <50% in baseline stenosis severity became
culprit lesions for future events, with a median follow-up time
of 1.22 years. In the same group, 25% of lesions with a>50%
baseline stenosis severity resulted in clinical events (Fig. 1).
Plaque Burden, Plaque Progression,
and Clinical Events: What Is the Evidence?
Historical data suggested that coronary stenosis severity
measured angiographically is associated with clinical
outcomes (30). Intravascular ultrasonography (IVUS) has
been pivotal in outlining the true burden of coronaryFigure 1 The COURAGE Angiographic Substudy
Index lesion characteristics of patients from the COURAGE trial who developed acute myoca
coronary intervention (PCI). ACS ¼ acute coronary syndrome(s); COURAGE ¼ Clinical Out
stenosis; MI ¼ myocardial infarction. Reproduced with permission from Mancini et al. (2atherosclerosis in vivo. Angiography has known limitations
for outlining the true extent of plaque burden (31). Although
some culprit lesions responsible for future AMI may appear
mild on an angiogram, these lesions invariably contain
signiﬁcant plaque burden, masked by an outward (expansive,
or positive) vessel remodeling process, as originally described
by Glagov et al. (32), later conﬁrmed using IVUS (33). There
is emerging evidence that the baseline burden of atheroscle-
rosis measured on IVUS is associated with future clinical
events (34,35). In the PROSPECT (Providing Regional
Observations to Study Predictors of Events in the Coronary
Tree) study, the major imaging predictors of subsequent
cardiovascular events included higher baseline plaque burden,
smaller lumen size, and the presence of an IVUS-derived thin-
cap ﬁbroatheroma (36). Although themean baseline diameter
stenosis severity of the 106 lesions in the PROSPECT study
that were responsible for major adverse cardiac events
(MACE) was 32%, these lesions progressed to a mean
diameter stenosis severity of 65% at the time of AMI, con-
ﬁrming the interval progression of plaques to a critical,
obstructive level of stenosis at the time of AMI. These ﬁnd-
ings were supported by a smaller, similarly designed study
(37). Such ﬁndings suggest that measures of plaque compo-
sition associate with cardiovascular events, in addition to
measures of plaque burden (36,37). Second-generation inva-
sive imaging tools of plaque composition may provide further
insights into the role of atheroma composition, mediating the
natural history of coronary atherosclerosis, response to ther-
apies, and resultant clinical events.
Acknowledging the limitations of angiography in ascer-
taining the true extent of arterial wall disease, a uniquerdial infarction (AMI) or acute coronary syndrome (ACS), or who needed percutaneous
comes Utilizing Revascularization and Aggressive Drug Evaluation; DS ¼ diameter
9).
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1137analysis undertaken by Yokoya et al. (14) involved analyzing
4 serial coronary angiograms performed at approximately
4-month intervals over a 1-year period in 36 patients.
Type 1 lesions were those that displayed marked interval
progression (deﬁned as 15% diameter stenosis angio-
graphic progression); type 2 lesions were those that
showed either slight (5% to 14% diameter stenosis) or
no (<5% diameter stenosis) progression. Myocardial in-
farction, marked disease progression, or angina pectoris
occurred in 71% of type 1 lesions. The wealth of serial
data of atherosclerosis progression in humans in vivo,
however, exists in the setting of clinical trials that utilized
serial IVUS to evaluate the efﬁcacy of antiatherosclerotic
therapies in nonobstructed (<50% diameter stenosis se-
verity) vessels. Regression of coronary atherosclerosis
occurred in patients with on-treatment low-density
lipoprotein cholesterol levels below 70 mg/dl (38–40),
and in those with modest elevations of high-density
lipoprotein cholesterol or via infusing lipid-deplete
forms of high-density lipoprotein cholesterol (41,42).
This highlights the efﬁcacy of systemic therapies in less
advanced, yet potentially vulnerable lesions that may
otherwise have demonstrated interval progression to
result in a clinical event. More recently, localized endo-
thelial shear stress was found to independently associate
with focal plaque progression (43). A pooled analysis of
over 4,000 patients in 6 clinical trials who underwent
serial coronary IVUS evaluation, identiﬁed the rate of
epicardial disease progression to independently associate
with clinical outcomes (34), largely driven by the need for
coronary revascularization. Similar ﬁndings were noted in
a recent analysis of left main coronary artery segments,
whereby plaque progression and constrictive remodeling
of the left main segment was associated with incident
clinical events (35).
Does Ischemia Equate to a
High-Risk Clinical Situation?
Of all the coronary lesions assessed daily in clinical practice,
cumulative evidence points to the fact that those lesions
conferring the greatest risk for subsequent events, are lesions
found to cause ischemia. When fractional ﬂow reserve (FFR)
was used to assess the functional signiﬁcance of a coronary
lesion, the chance of mortality or AMI over a 5-year period
appeared to be 5-fold higher in patients harboring a func-
tionally signiﬁcant coronary lesion (evaluated as having an
FFR <0.75), as opposed to functionally insigniﬁcant lesions
(44). These observations with FFR are supported by a wealth
of data from noninvasive imaging studies that highlight the
adverse prognosis of ischemia-producing lesions in causing
AMI or death (45,46). The COURAGE nuclear substudy
demonstrated an association between ischemia reduction (by
either PCI or medical therapy) and lower long-term rates of
death or AMI (47). A separate analysis of COURAGE
showed that worsening of ischemia, on serial single-photonemission computed tomography, was also an independent
predictor of death or AMI (48).
More recently, the FAME 2 (Fractional Flow Reserve
Versus Angiography for Multivessel Evaluation 2) trial
evaluated patients with stable angina and documented
coronary disease, with identiﬁed lesions undergoing
FFR evaluation (49). The aim was to test the hypothesis
that PCI plus the best available medical therapy would
be superior in reducing the rate of death, MI, or urgent
coronary revascularization, compared with best available
medical therapy alone. Patients who had no proven
functionally signiﬁcant lesion by FFR were enrolled into
a registry and managed with optimal medical therapy.
Although there were signiﬁcant differences for the pri-
mary endpoint in favor of patients undergoing PCI
(driven largely by reductions in the need for urgent cor-
onary revascularization), patients enrolled into the registry
had equivalent clinical outcomes to the PCI group. The
angiographic ﬁndings of this group were not dissimilar to
the randomized cohort, with 90% of patients having at
least 1 epicardial stenosis of >50% diameter. The absence
of a functionally signiﬁcant epicardial lesion, despite the
angiographic ﬁndings, portended a 3% occurrence of
the primary endpoint, compared with 12.7% in the me-
dically treated group (p < 0.001). A 4.3% rate of the
primary endpoint in the PCI-treated group, compared
evenly with those patients without a functionally signiﬁ-
cant epicardial lesion (p ¼ 0.61). In addition, despite the
trial being underpowered and stopped early, there was
a trend toward a 39% relative risk reduction in death or
AMI in the PCI-treated group compared with the
medically treated group (hazard ratio [95% conﬁdence
interval]: 0.61 [0.28 to 1.35], p ¼ 0.22). Acknowledging
the various limitations of this trial, the FAME 2 result
underscores the importance of the presence of functionally
signiﬁcant epicardial lesion as an adverse prognosticator
in the short to medium term.
Further to this reasoning, Bangalore at al. (50) undertook
a meta-analysis in an attempt to evaluate the association
of PCI compared with optimal medical therapy, in stable
patients with ischemic coronary artery disease, on the oc-
currence of various types of MI: either spontaneous non-
procedural MI, procedural-related MI, or “all MI,” which
included procedural MI. Although PCI for stable, obstruc-
tive lesions reduced the rate of spontaneous MI, this
occurred at the expense of a higher risk of procedural-related
MI. However, spontaneous MI carried a considerably higher
risk of mortality than procedural-related MI, such that the
point estimate for reduced mortality with PCI compared
with medical therapy alone paralleled the prevention of
spontaneous MI following PCI. These results provide a level
of support to the ﬁndings of FAME 2 in that functionally
signiﬁcant lesions noted in angiography are commonly
obstructive (>50% diameter stenosis, and thus amenable for
revascularization), and are thus not “mild,” and do not
necessarily have a benign course despite the use of optimal
Puri et al. JACC Vol. 63, No. 12, 2014
Ischemia, Plaque Burden, and Disease Progression April 1, 2014:1134–40
1138medical therapies. Although such lesions may not strictly
conform to the consensus deﬁnition of a pathological
vulnerable plaque, such lesions could be considered high risk
from a clinical perspective.Implications for Future
Vulnerable Plaque Imaging Trials
Contemporary medical therapies, particularly dual anti-
platelet and high-intensity statin therapies, have undoubt-
edly altered the natural history of coronary atherosclerosis,
and curbed subsequent clinical event rates, even in patients
considered at greatest risk for secondary coronary events.
Indeed, MACE rates in the PROSPECT, PREDICTION
(Prediction of Progression of Coronary Artery Disease
and Clinical Outcome Using Vascular Proﬁling of Shear
Stress and Wall Morphology), and FAME 2 trials were
largely driven by the need for repeat coronary revasculari-
zation (36,43,49), considered by many to not represent
a “hard” clinical event. However, it is important to note that
percutaneous coronary revascularization per se, even for
stable ischemic or functionally signiﬁcant coronary lesions,
should not necessarily be considered a benign undertaking,
as there are inherent risks attributable to this procedure (50),
and revascularization may indeed improve the morbidity
and mortality of these patients (50–52). These observations
have made the task for natural history studies of coronary
atheroma rather difﬁcult to draw strong associations betweenFigure 2 Proposed Pathway of Coronary Lesions Leading to AMI
There are a number of pathways that result in lesions causing acute myocardial infarctio
greatest propensity for causing myocardial infarction are those that are at least 50% sten
ischemic. FFR ¼ fractional ﬂow reserve; WSS ¼ wall shear stress.incident hard clinical events and underlying plaque mor-
phology. Although ethically feasible to undertake intravas-
cular imaging in patients undergoing a clinically indicated
coronary angiogram, it is highly unethical to deny patients
the best available medical therapy following acute coronary
syndromes. This has important implications for the design
of studies that attempt to link prospective hard clinical
events with de novo coronary plaque phenotype.
In the current era, evidence and guidelines support lo-
wering of low-density lipoprotein cholesterol levels to below
70 mg/dl in patients with coronary disease, resulting in
coronary atheroma regression in a majority of individuals
(39,40). As such, are hard clinical events still the most
appropriate endpoints for imaging studies of coronary
atherosclerosis? Rather, should primary endpoints of im-
aging trials focus on the surrogate marker of disease
progression despite optimal medical therapies? One such
proposition is to consider the “softer” ﬁndings of plaque/
lesion progression and/or coronary revascularization as valid
surrogate endpoints in clinical studies assessing potential
vulnerable plaque phenotype in a secondary preventive
setting. As witnessed in FAME 2, 50% of patients requiring
urgent coronary revascularization presented with either
a biomarker-positive acute coronary syndrome, or with is-
chemic electrocardiographic abnormalities (49). Although
these are not desirable clinical endpoints in clinical outcomes
trials, the alternative would be to undertake a clinical
outcomes trial in huge numbers of patients with extendedn (AMI). On the basis of current clinical evidence, we propose that lesions with the
otic on a coronary angiogram, that undergo rapid lesion progression, and/or that are
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1139(>5 years) clinical follow-up in order to draw clinically
meaningful associations between vulnerable plaque pheno-
type and hard coronary events. Indeed, the ﬁnancial impli-
cations of conducting such a trial may prove prohibitive. It
may thus be necessary to broaden the scope of coronary
imaging studies to include the potential evaluation of
asymptomatic patients considered intermediate-to-high
cardiovascular risk for AMI, in order to capture more of
the >1 million people annually that succumb to AMI or its
complications in the United States alone. This would,
however, require the use of noninvasive coronary imaging,
which currently lacks the imaging resolution and technology
to reliably image targets of plaque vulnerability within the
coronary arterial wall. Furthermore, the lower clinical event
rate observed in a more general population, coupled with the
lower diagnostic accuracy of these noninvasive imaging
tools, is likely to lead to a reduced sensitivity and speciﬁcity.
This, however, may be overcome by enriching the studied
population via known (or soon-to-be validated) plasma
biomarkers that relate to future MACE. One such current
example is the current controversial role of systemic
inﬂammation (plasma C-reactive protein levels) in providing
incremental risk-predictive capabilities beyond cholesterol
levels (53). Thus, the interplay between high plaque burden
and composition, lesion progression, lesion-related ischemia,
and high C-reactive protein levels may more readily opti-
mize the identiﬁcation of vulnerable patients that harbor
high-risk plaque more likely to associate with an incident
clinical event. Efforts are already underway to utilize various
noninvasive imaging and plasma biomarkers for prospective
risk assessment in individuals without known athero-
thrombotic disease, yet considered at risk for short- to
intermediate-term cardiovascular events (54).
Conclusions
Contemporary analyses demonstrate that many AMIs could
arise from obstructive lesions (>50% angiographic stenosis
severity), either close to or at the time of the event. Before
causing an AMI, it is possible that these lesions harbored
ischemic potential, possessing a critical, large burden of
plaque that remained susceptible to repeated cycles of plaque
rupture and intraplaque hemorrhage. This sets the substrate
for further plaque progression, lumen encroachment and
unstable symptoms, and/or uncontained in situ thrombosis
and subsequent AMI (Fig. 2). In addition, we propose that
lesions containing large plaque burden and/or ischemic
potential within at-risk patients, should be the focus of
imaging evaluation in the setting of appropriately designed
clinical studies to identify processes that drive lesion
progression and promote lesion instability.
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